(1R,2R,4S)-N-Boc-1-氨基-2-羟基环戊烷-4-羧酸甲酯 | 321744-16-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1R,2R,4S)-N-Boc-1-氨基-2-羟基环戊烷-4-羧酸甲酯
• 中文别名: (1R,2R,4S)-N-BOC-1-氨基-2-羟基环戊烷-4-甲酸甲酯
• 英文名称: (1R,2R,4S)-1-(tert-butoxycarbonylamino)-2-hydroxycyclopentane-4-carboxylic acid methyl ester
• 英文别名: (1S,3R,4R)-3-tert-butoxycarbonylamino-4-hydroxycyclopentanecarboxylic acid methyl ester；methyl (1S,3R,4R)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentane-1-carboxylate
• CAS: 321744-16-5
• 化学式: C₁₂H₂₁NO₅
• 分子量: 259.302
• InChiKey: SSATZBUCOTXXGA-DJLDLDEBSA-N

物化性质

• 沸点：
  402.56°C (rough estimate)
• 密度：
  1.1623 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 安全说明：
  S24/25

SDS

Name:	(1R 2R 4S)-N-BOC-1-Amino-2-hydroxycyclopentane-4-carboxylic acid Material Safety Data Sheet
Synonym:	Methyl (1S,3R,4R)-N-BOC-3-amino-4-hydroxycyclopentanecarboxylat
CAS:	321744-16-5

Section 1 - Chemical Product MSDS Name:(1R 2R 4S)-N-BOC-1-Amino-2-hydroxycyclopentane-4-carboxylic acid Material Safety Data Sheet
Synonym:Methyl (1S,3R,4R)-N-BOC-3-amino-4-hydroxycyclopentanecarboxylat

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
321744-16-5	(1R,2R,4S)-N-BOC-1-Amino-2-hydroxycycl	95	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 321744-16-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Not available.
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H21NO5
Molecular Weight: 259.3

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 321744-16-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(1R,2R,4S)-N-BOC-1-Amino-2-hydroxycyclopentane-4-carboxylic - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 321744-16-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 321744-16-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 321744-16-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (1R,2R,4S)-N-Boc-1-氨基-2-羟基环戊烷-4-羧酸甲酯 在 盐酸 、 三乙胺 作用下， 以 水 、 乙腈 为溶剂， 反应 7.0h， 生成 (1S,3R,4R)-3-(9-fluorenylmethoxycarbonylamino)-4-hydroxycyclopentanecarboxylic acid
  参考文献：
  名称：

  将氨基环戊烷羧酸接枝到RGD三肽序列上会产生低纳摩尔浓度的alphaVbeta3 / alphaVbeta5整联蛋白双结合剂。

  摘要：

  以手性非外消旋形式制备了11个γ-氨基环戊烷羧酸（Acpca）平台，包括四个二羟基代表分子（19-22），三个羟基类似物（34-36）和四个脱氧衍生物（30-33）。然后通过混合固相/溶液方案将这些简单的单元嫁接到Arg-Gly-Asp（RGD）三肽构架上，从而提供11种环-[-Arg-Gly-Asp-Acpca-]型大环类似物的集合体-11。评价各个化合物对αVbeta3和αVbeta5整联蛋白受体的结合亲和力。与参考化合物EMD121974和ST1646相比，类似物10表现出非常有趣的活性谱（IC50 / alphaVbeta3 = 1.5 nM； IC50 / alphaVbeta5 = 0.59 nM）。密切相关的同类物6、8 和9也被证明是出色的双重粘合剂，其活性水平在低纳摩尔范围内。确定了三维（3D）NMR溶液结构，并在选定的类似物上与参照化合物EMD121974进行了整合素α

  DOI：

  10.1021/jm050698x
• 作为产物：
  描述：

  (1S,4R)-4-甲基环戊-2-烯甲酸甲酯盐酸盐 在 palladium on activated charcoal 4-二甲氨基吡啶 、 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 TEA 、 氢气 、 sodium methylate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 90.0 ℃ 、241.32 kPa 条件下， 反应 204.0h， 生成 (1R,2R,4S)-N-Boc-1-氨基-2-羟基环戊烷-4-羧酸甲酯
  参考文献：
  名称：

  An efficient route to all eight stereoisomers of a tri-functionalised cyclopentane scaffold for drug discovery

  摘要：

  A route to all eight stereoisomers of 3-(tert-butoxycarbonylamino)-4-hydroxycyclopentanecarboxylic acid methyl ester is presented; these products should prove to be valuable scaffolds in pharmaceutical discovery. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00108-2

文献信息

• Use of hydrolases for the synthesis of cyclic amino acids
  作者：Richard C Lloyd、Michael C Lloyd、Mark E.B Smith、Karen E Holt、Jonathan P Swift、Philip A Keene、Stephen J.C Taylor、Raymond McCague

  DOI：10.1016/j.tet.2003.10.116

  日期：2004.1

  The synthesis of several cyclic amino acids that have all the necessary structural features to make them ideal scaffolds for use in medicinal chemistry is described. A key step in each synthesis is the use of hydrolase enzymes to define a chiral centre. In order to elaborate these building blocks into more complex molecules, crystallization and asymmetric hydrogenation were used to define further stereocentres

  描述了具有所有必要结构特征以使其成为用于药物化学的理想支架的几种环状氨基酸的合成。每个合成过程中的关键步骤是使用水解酶来定义手性中心。为了将这些结构单元详细化为更复杂的分子，使用了结晶和不对称氢化来定义进一步的立体中心。
• Highly selective directed hydrogenation of enantiopure 4-( tert -butoxycarbonylamino)cyclopent-1-enecarboxylic acid methyl esters
  作者：Mark E.B Smith、Nadine Derrien、Michael C Lloyd、Stephen J.C Taylor、David A Chaplin、Raymond McCague

  DOI：10.1016/s0040-4039(00)02210-3

  日期：2001.2

  The use of both N-tert-butoxycarbonylamino- and hydroxyl-directed hydrogenation methodology to yield essentially single diastereomers of 3-(tert-butoxycarbonylamino)-4-hydroxycyclopentanecarboxylic acid methyl esters and 3-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid methyl esters is described. These results incorporate the first reported carbamate-directed hydrogenations of functionalised

  同时使用的ñ -叔叔丁氧羰和羟基定向加氢方法得到的3-基本上单非对映体（叔丁氧基羰基）-4- hydroxycyclopentanecarboxylic酸甲酯和3-（叔丁氧基羰基）环戊烷羧酸甲酯进行说明。这些结果结合了第一个报道的官能化环戊烯的氨基甲酸酯定向加氢反应。
• Renin Inhibitors
  申请人：Baldwin John J.

  公开号：US20090264428A1

  公开（公告）日：2009-10-22

  Described are compounds of the formula (I) which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.

  本文描述了一种公式（I）的化合物，其具有口服活性并能结合天冬氨酸蛋白酶以抑制其活性。它们可用于治疗或改善与天冬氨酸蛋白酶活性相关的疾病。还描述了在需要改善或治疗天冬氨酸蛋白酶相关疾病的受试者中使用本文所述化合物的方法。
• RENIN INHIBITORS
  申请人：Baldwin John J.

  公开号：US20090275581A1

  公开（公告）日：2009-11-05

  Disclosed are compounds according to Formula I: wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.

  本发明涉及公式I所示的化合物，其中变量在此定义。这些化合物能够结合天冬氨酸蛋白酶以抑制其活性。它们可用于治疗或改善与天冬氨酸蛋白酶活性相关的疾病。本发明还描述了拮抗需要受到天冬氨酸蛋白酶抑制剂的受试者的方法，包括向受试者施用公式I所示的化合物的治疗有效量。
• CYCLOALKANE-1,3-DIAMINE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3892278A1

  公开（公告）日：2021-10-13

  The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

  本发明提供了一种化合物或其药学上可接受的盐，对 Menin 与 MLL 蛋白之间的相互作用具有抑制作用。式（1）所代表的化合物或其药学上可接受的盐。 其中，在式(1)中，虚圈、R1、R2、R3、R4、R5、R6、R7、R8、环Q1、W、m和n各自如描述中所定义。